VFEND 200 MG POWDER FOR SOLUTION FOR INFUSION

Country: Iżrael

Lingwa: Ingliż

Sors: Ministry of Health

Ingredjent attiv:

VORICONAZOLE 200 MG/VIAL

Disponibbli minn:

PFIZER PHARMACEUTICALS ISRAEL LTD

Kodiċi ATC:

J02AC03

Għamla farmaċewtika:

POWDER FOR SOLUTION FOR INFUSION

Rotta amministrattiva:

I.V

Manifatturat minn:

PFIZER PGM, FRANCE

Grupp terapewtiku:

VORICONAZOLE

Indikazzjonijiet terapewtiċi:

Treatment of : - invasive aspergillosis fluconazole-resistant serious invasive Candida infections (including C. krusei), - serious fungal infections caused by scedosporium spp. and fusarium spp.Vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. Treatment of candidemia in non neutropenic patients.

Data ta 'l-awtorizzazzjoni:

2012-10-01